Celsius Therapeutics signs collaboration agreement with Janssen to identify response biomarkers for ulcerative colitis

This article was originally published here

Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify predictive biomarkers of response from Janssen’s VEGA study, a

The post Celsius Therapeutics signs collaboration agreement with Janssen to identify response biomarkers for ulcerative colitis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply